114 related articles for article (PubMed ID: 27976416)
1. Effects of nucleoside analogue prescription for hepatitis B on the incidence of liver cancer in Hong Kong: a territory-wide ecological study.
Seto WK; Lau EH; Wu JT; Hung IF; Leung WK; Cheung KS; Fung J; Lai CL; Yuen MF
Aliment Pharmacol Ther; 2017 Feb; 45(4):501-509. PubMed ID: 27976416
[TBL] [Abstract][Full Text] [Related]
2. Long-term use of oral nucleos(t)ide analogues for chronic hepatitis B does not increase cancer risk - a cohort study of 44 494 subjects.
Wong GL; Tse YK; Yip TC; Chan HL; Tsoi KK; Wong VW
Aliment Pharmacol Ther; 2017 May; 45(9):1213-1224. PubMed ID: 28239880
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analogue therapy.
Hung CH; Wang JH; Lu SN; Hu TH; Lee CM; Chen CH
J Viral Hepat; 2017 Jul; 24(7):599-607. PubMed ID: 28130815
[TBL] [Abstract][Full Text] [Related]
4. Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis.
Hsiang JC; Wong GL; Tse YK; Wong VW; Yip TC; Chan HL
J Hepatol; 2015 Nov; 63(5):1190-7. PubMed ID: 26208777
[TBL] [Abstract][Full Text] [Related]
5. Virological efficacy of combination therapy with corticosteroid and nucleoside analogue for severe acute exacerbation of chronic hepatitis B.
Yasui S; Fujiwara K; Nakamura M; Miyamura T; Yonemitsu Y; Mikata R; Arai M; Kanda T; Imazeki F; Oda S; Yokosuka O
J Viral Hepat; 2015 Feb; 22(2):94-102. PubMed ID: 24750410
[TBL] [Abstract][Full Text] [Related]
6. The 5-year cumulative incidence of HCC development and treatment regimen in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment.
Wang S; Fang S; Liu Y
J Viral Hepat; 2021 Sep; 28(9):1333-1334. PubMed ID: 34051028
[No Abstract] [Full Text] [Related]
7. Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic.
Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Tanaka J
J Gastroenterol Hepatol; 2017 Feb; 32(2):451-458. PubMed ID: 27288655
[TBL] [Abstract][Full Text] [Related]
8. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.
Seto WK; Wong DK; Fung J; Huang FY; Lai CL; Yuen MF
Hepatology; 2013 Sep; 58(3):923-31. PubMed ID: 23468172
[TBL] [Abstract][Full Text] [Related]
9. Body-mass index is associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B.
Seto WK; Fung J; Cheung KS; Mak LY; Hui RW; Liu KS; Lai CL; Yuen MF
Aliment Pharmacol Ther; 2016 Nov; 44(10):1071-1079. PubMed ID: 27659292
[TBL] [Abstract][Full Text] [Related]
10. Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong.
Lee KK; Wu DB; Chow PY; Lee VW; Li H
J Gastroenterol Hepatol; 2012 Jul; 27(7):1167-74. PubMed ID: 22141402
[TBL] [Abstract][Full Text] [Related]
11. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation.
Fung J; Cheung C; Chan SC; Yuen MF; Chok KS; Sharr W; Dai WC; Chan AC; Cheung TT; Tsang S; Lam B; Lai CL; Lo CM
Gastroenterology; 2011 Oct; 141(4):1212-9. PubMed ID: 21762659
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area.
Ungtrakul T; Mahidol C; Chun-On P; Laohapand C; Siripongsakun S; Worakitsitisatorn A; Vidhayakorn S; Boonchuay W; Dechma J; Sornsamdang G; Soonklang K; Sriprayoon T; Tanwandee T; Auewarakul CU
World J Gastroenterol; 2016 Sep; 22(34):7806-12. PubMed ID: 27678364
[TBL] [Abstract][Full Text] [Related]
13. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study.
Wu CY; Lin JT; Ho HJ; Su CW; Lee TY; Wang SY; Wu C; Wu JC
Gastroenterology; 2014 Jul; 147(1):143-151.e5. PubMed ID: 24704525
[TBL] [Abstract][Full Text] [Related]
14. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
Coffin CS; Rezaeeaval M; Pang JX; Alcantara L; Klein P; Burak KW; Myers RP
Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1262-9. PubMed ID: 25312649
[TBL] [Abstract][Full Text] [Related]
15. Transarterial chemoembolization for hepatitis B virus-associated hepatocellular carcinoma: improved survival after concomitant treatment with nucleoside analogues.
Toyoda H; Kumada T; Tada T; Sone Y; Fujimori M
J Vasc Interv Radiol; 2012 Mar; 23(3):317-22.e1. PubMed ID: 22265248
[TBL] [Abstract][Full Text] [Related]
16. Long-term lamivudine for chronic hepatitis B and cirrhosis: A real-life cohort study.
Su MH; Lu AL; Li SH; Zhong SH; Wang BJ; Wu XL; Mo YY; Liang P; Liu ZH; Xie R; He LX; Fu WD; Jiang JN
World J Gastroenterol; 2015 Dec; 21(46):13087-94. PubMed ID: 26673249
[TBL] [Abstract][Full Text] [Related]
17. Etiologies of chronic liver diseases in Hong Kong.
Fung KT; Fung J; Lai CL; Yuen MF
Eur J Gastroenterol Hepatol; 2007 Aug; 19(8):659-64. PubMed ID: 17625435
[TBL] [Abstract][Full Text] [Related]
18. Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy.
Hwang JP; Suarez-Almazor ME; Cantor SB; Barbo A; Lin HY; Ahmed S; Chavez-MacGregor M; Donato-Santana C; Eng C; Ferrajoli A; Fisch MJ; McLaughlin P; Simon GR; Rondon G; Shpall EJ; Lok AS
Cancer; 2017 Sep; 123(17):3367-3376. PubMed ID: 28518219
[TBL] [Abstract][Full Text] [Related]
19. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B.
Singal AK; Salameh H; Kuo YF; Fontana RJ
Aliment Pharmacol Ther; 2013 Jul; 38(2):98-106. PubMed ID: 23713520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
